undamentalytics Newsletter
Sign in

Janux Therapeutics, Inc. (JANX) stock

Add to watchlist

Add holding +

NASDAQ: JANX Nasdaq Biotechnology Next results ~November 5, 2026

C+ Fundamentals grade

Janux Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$13

Valuation models combined (2)

Base case. Range ~$8.8–$15. Weighted average of 2 models (growth cash-flow model, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Janux Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
  • Funds117 adding, 74 cuttingOf 48 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Janux Therapeutics files

Where Janux Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $24m, up 5367.0% on a year earlier, faster than the 47.1% growth a quarter earlier. That growth ranks 4 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -174.7% from -13827.8% a year earlier. Operating margin widened to -598.1% from -33002.1%. The diluted share count is up 6.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $10.06 a share, against a share price of $18.32.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Janux Therapeutics, Inc.'s trailing-twelve-month revenue grew 5367.0% year on year, with a free-cash-flow margin of -174.7%. Where it stands out: change in growth rate of +5319.9pp ranks 3 of 172 biotechnology companies we cover. Where it lags: stock pay as % of revenue of 153.7% ranks 149 of 179 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 5367.0% (+5319.9pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 5367.0% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 5319.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 32403.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -598.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -174.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 153.7% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 6.2% in a year.
  • High sales multiple. The shares trade at 45 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.35 against an average estimate of -$0.29: missed by 20.9%
Revenue
$10m
Share reaction
-0.9% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.49

Janux Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.1%
  • 1 week+4.6%
  • 1 month+3.1%
  • This year+26.5%
  • 1 year-39.2%
  • 5 years-34.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$24M
Operating margin
-598.1%
Net margin
-427.5%
EPS (TTM, diluted)
$-1.64

Growth

Revenue growth
+5367.0%
Change in growth rate
+5319.9 pts
Share count change
+6.2%

Cash

Free cash flow (TTM)
-$41.9M
FCF margin
-174.7%
Stock pay % of revenue
153.7%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Janux Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Janux Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$15 ~$15–$15 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.4 ~$0.4–$1.6 Left out: out of range vs price (0.02x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$8.8 ~$8.1–$9.5 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$13 ~$8.8–$15 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Janux Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$19.73$13.17$10.73$53.54$13.80$17.46
Market value$464m$546m$472m$2.9bn$855m$1.1bn
+ Net debt (− = net cash)−$36m−$51m−$19m−$431m−$52m−$28m
Enterprise value$429m$495m$453m$2.4bn$803m$1.1bn
Multiples
Price / sales 127.6x63.4x58.4xn/m85.5x45.4x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Janux Therapeutics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -10.2% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -908.1%; its worst year was -33002.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -483.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $6m and EPS of −$0.49 (range −$0.67 to −$0.04) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.73 +5% $29m +194%
Next −$2.62 −52% $8m −73%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.8% on 90 days ago. In the last 30 days, 7 analysts raised Janux Therapeutics, Inc.'s forecast and 5 cut it.

Consensus EPS forecast Janux Therapeutics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.76 Current fiscal year, 60 days ago: −$1.76 Current fiscal year, 30 days ago: −$1.73 Current fiscal year, 7 days ago: −$1.73 Current fiscal year, Now: −$1.73 −$1.73 Next fiscal year, 90 days ago: −$2.70 Next fiscal year, 60 days ago: −$2.64 Next fiscal year, 30 days ago: −$2.62 Next fiscal year, 7 days ago: −$2.62 Next fiscal year, Now: −$2.62 −$2.62

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.76−$2.70
60 days ago −$1.76−$2.64
30 days ago −$1.73−$2.62
7 days ago −$1.73−$2.62
Now −$1.73−$2.62

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.29 −$0.35 −20.9%
Mar 2026 −$0.52 −$0.39 +25.0%
Dec 2025 −$0.64 −$0.51 +20.5%
Sept 2025 −$0.61 −$0.39 +36.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Janux Therapeutics, Inc.'s latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

18 analysts, Oct 2026
Buy1689%
Hold16%
Sell16%

Monthly trend

  1. Oct 202621418
  2. Sep 202621418
  3. Aug 202621418

Counts of recommendations published by analysts covering Janux Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.1%
of tradable shares
Days to cover
5.72
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.0%
of shares
Employees
113
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −39.2%

$28.71 on October 31, 2025 to $17.46

ThenNowEffect
Revenue (last 12 months) $439000 $24m +5367.0%
P/S multiple n/m 45.4x −98.8%
Share count 59m 62m −5.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +157.9%

$6.77 on November 3, 2023 to $17.46

ThenNowEffect
Revenue (last 12 months) $8m $24m +209.2%
P/S multiple 36.3x 45.4x +25.0%
Share count 42m 62m −33.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
JANX−33%−19%+399%−74%+27%
Industry peers (median)−57%−17%−29%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
JANX50%50%42%42%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
JANX−53%−74%−46%−76%−20%
S&P 500−25%−10%−8%−19%−9%

Worst fall since June 11, 2021: 83% from August 5, 2021 to November 9, 2023. Getting back needed a 493% gain, reached on February 27, 2024, 110 days after the low.

Price behaviour

52-week range
$12.18 – $34.74
From 52-week high
−49.7%
vs 50-day average
−0.8%
vs 200-day average
+13.8%
Volatility (1 year)
71%
Beta vs S&P 500
1.11

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±3.4%
After a week
4 up, 8 down
typical move ±8.0%
After a month
6 up, 6 down
typical move ±16.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −0.9% +0.5% 0.0% +26.5%
May 7, 2026 −3.0% +0.5% −1.6% −7.6%
February 26, 2026 −0.7% −1.0% +2.0% −3.8%
November 6, 2025 −3.8% −1.0% −0.3% −39.8%
August 7, 2025 −5.6% +0.7% +3.3% +2.6%
May 8, 2025 −0.5% +0.6% −9.5% +0.9%
February 27, 2025 +0.9% −0.1% −5.7% −10.7%
November 6, 2024 −1.9% +3.3% −6.0% +17.6%
August 7, 2024 −1.1% +1.6% +8.9% +11.8%
May 8, 2024 −15.5% +0.6% −22.8% −28.2%
March 8, 2024 −1.6% −0.7% −2.9% −1.4%
November 7, 2023 +5.9% +0.4% +33.3% +50.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Janux Therapeutics, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Janux Therapeutics, Inc.
$0 $10M $20M $30M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $8.5M Revenue (TTM), FY23 Q4: $8.1M Revenue (TTM), FY24 Q1: $7.3M Revenue (TTM), FY24 Q2: $15.1M Revenue (TTM), FY24 Q3: $13M Revenue (TTM), FY24 Q4: $10.6M Revenue (TTM), FY25 Q1: $9.3M Revenue (TTM), FY25 Q2: $439K Revenue (TTM), FY25 Q3: $10M Revenue (TTM), FY25 Q4: $10M Revenue (TTM), FY26 Q1: $13.7M Revenue (TTM), FY26 Q2: $24M $24M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $8.5M
FY23 Q4 $8.1M
FY24 Q1 $7.3M
FY24 Q2 $15.1M
FY24 Q3 $13M
FY24 Q4 $10.6M
FY25 Q1 $9.3M
FY25 Q2 $439K
FY25 Q3 $10M
FY25 Q4 $10M
FY26 Q1 $13.7M
FY26 Q2 $24M
Revenue growth, TTM YoY Janux Therapeutics, Inc.
-2000% 0% 2000% 4000% 6000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 14.7% Revenue growth, TTM YoY, FY23 Q4: -6.1% Revenue growth, TTM YoY, FY24 Q1: -19.7% Revenue growth, TTM YoY, FY24 Q2: 94.9% Revenue growth, TTM YoY, FY24 Q3: 54.1% Revenue growth, TTM YoY, FY24 Q4: 31.0% Revenue growth, TTM YoY, FY25 Q1: 28.1% Revenue growth, TTM YoY, FY25 Q2: -97.1% Revenue growth, TTM YoY, FY25 Q3: -23.4% Revenue growth, TTM YoY, FY25 Q4: -5.6% Revenue growth, TTM YoY, FY26 Q1: 47.1% Revenue growth, TTM YoY, FY26 Q2: 5367.0% 5367.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 14.7%
FY23 Q4 -6.1%
FY24 Q1 -19.7%
FY24 Q2 94.9%
FY24 Q3 54.1%
FY24 Q4 31.0%
FY25 Q1 28.1%
FY25 Q2 -97.1%
FY25 Q3 -23.4%
FY25 Q4 -5.6%
FY26 Q1 47.1%
FY26 Q2 5367.0%
Operating margin (TTM) Janux Therapeutics, Inc.
-40000% -30000% -20000% -10000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -887.1% Operating margin (TTM), FY23 Q4: -902.9% Operating margin (TTM), FY24 Q1: -999.8% Operating margin (TTM), FY24 Q2: -435.9% Operating margin (TTM), FY24 Q3: -658.8% Operating margin (TTM), FY24 Q4: -933.6% Operating margin (TTM), FY25 Q1: -1216.6% Operating margin (TTM), FY25 Q2: -33002.1% Operating margin (TTM), FY25 Q3: -1442.9% Operating margin (TTM), FY25 Q4: -1576.7% Operating margin (TTM), FY26 Q1: -1143.1% Operating margin (TTM), FY26 Q2: -598.1% -598.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -887.1%
FY23 Q4 -902.9%
FY24 Q1 -999.8%
FY24 Q2 -435.9%
FY24 Q3 -658.8%
FY24 Q4 -933.6%
FY25 Q1 -1216.6%
FY25 Q2 -33002.1%
FY25 Q3 -1442.9%
FY25 Q4 -1576.7%
FY26 Q1 -1143.1%
FY26 Q2 -598.1%
FCF margin (TTM) Janux Therapeutics, Inc.
-15000% -10000% -5000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -661.1% FCF margin (TTM), FY23 Q4: -648.6% FCF margin (TTM), FY24 Q1: -730.9% FCF margin (TTM), FY24 Q2: -315.6% FCF margin (TTM), FY24 Q3: -289.8% FCF margin (TTM), FY24 Q4: -417.2% FCF margin (TTM), FY25 Q1: -498.4% FCF margin (TTM), FY25 Q2: -13827.8% FCF margin (TTM), FY25 Q3: -714.0% FCF margin (TTM), FY25 Q4: -832.8% FCF margin (TTM), FY26 Q1: -571.6% FCF margin (TTM), FY26 Q2: -174.7% -174.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -661.1%
FY23 Q4 -648.6%
FY24 Q1 -730.9%
FY24 Q2 -315.6%
FY24 Q3 -289.8%
FY24 Q4 -417.2%
FY25 Q1 -498.4%
FY25 Q2 -13827.8%
FY25 Q3 -714.0%
FY25 Q4 -832.8%
FY26 Q1 -571.6%
FY26 Q2 -174.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 4 9 8 11 10 24
EBITDA −5 −33 −66 −71 −97 −156 −142
Operating income −5 −33 −67 −73 −99 −158 −144
Net income −7 −33 −63 −58 −69 −114 −103
Diluted EPS −$7.41 −$1.39 −$1.52 −$1.32 −$1.28 −$1.83 −$1.64
Growth (year on year)
Revenue — — +136.8% −6.1% +31.0% −5.6% +>999%
Margins
EBITDA margin — −902.3% −769.3% −878.7% −914.1% <−999% −590.2%
Operating margin — −905.4% −779.0% −902.9% −933.6% <−999% −598.1%
Net margin — −898.3% −732.2% −721.2% −651.6% <−999% −427.5%
Free-cash-flow margin — −507.5% −573.2% −648.6% −417.2% −832.8% −174.7%
Cash flow
Cash from operations −4 −17 −43 −51 −44 −82 −41
Capital spending 0 1 6 2 0 1 1
Free cash flow −4 −18 −49 −52 −44 −83 −42
Stock-based pay 0 7 17 20 33 40 37
Free cash flow after stock pay −4 −25 −67 −72 −77 −123 −79
Balance sheet
Cash 8 36 51 19 431 52 28
Total debt 0 0 0 0 0 0 0
Net debt (negative = net cash) −8 −36 −51 −19 −431 −52 −28
Diluted shares — 24m 41m 44m 54m 62m 62m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.0bn
Short-term assets $983mLonger-term assets $24m
What it owes, and who funded it · $1.0bn
Short-term liabilities $60mLonger-term liabilities $20mShareholders' equity $928m
  • Short-term assets cover short-term liabilities $983m of assets due within a year against $60m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $983m short-term assets against $20m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Janux Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+6.2%
year over year
R&D spending
516.6%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated JANX CRSP ABEO STOK GLUE TNXP Median
Revenue, last 12 months $24m $25m $26m $28m $29m $29m $56m
Revenue growth, last 12 months >999% −34.3% −87.7% −86.2% −83.9% 196.0% 12.6%
Revenue growth, 3-year average 45.7% −47.1% 212.0% 46.1% — — 13.7%
Revenue growth, latest quarter >999% >999% >999% −32.5% −61.3% 577.9% 10.2%
Gross margin — — 67.1% — — 83.8% 82.9%
Operating margin −598.1% <−999% −327.6% −809.7% −633.0% −568.4% −189.4%
Operating margin, 3-year average <−999% <−999% <−999% −515.1% <−999% −881.2% −363.5%
Net margin −427.5% <−999% −246.4% −753.6% −560.8% −548.6% −169.8%
Cash from operations / revenue −171.9% <−999% −299.5% −645.2% −83.8% −525.7% −168.0%
Free-cash-flow margin −174.7% <−999% −319.5% −654.9% −111.7% −543.3% −162.4%
Free-cash-flow margin, 3-year average <−999% −793.9% <−999% −385.4% −424.9% −605.0% −310.0%
Stock pay / revenue 153.7% 276.8% 45.4% 135.7% 71.7% 27.3% 20.0%
Change in share count 6.2% 10.0% 36.6% 7.1% 11.9% — 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 5367.0% 12.6% 5 of 172
Change in growth rate Growth +5319.9pp -0.1pp 3 of 172
Operating margin Profitability -598.1% -189.4% 124 of 175
Net margin Profitability -427.5% -157.3% 121 of 180
Free-cash-flow margin Cash generation -174.7% -145.4% 93 of 176
Stock pay as % of revenue Cash generation 153.7% 19.2% 149 of 179
Change in share count Balance sheet 6.2% 7.9% 73 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$946M
Institutions reporting
194
Shares held vs prior quarter
▲ 3.4%
Positions opened / closed
36 / 29

Top buyers and sellers, Q2 2026: 117 institutions bought and 74 sold ; the biggest buyer was Federated Hermes, Inc (+2.3M shares) and the biggest seller Deep Track Capital, LP (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $172M 11.2M 18.2% 0.0%
Blackrock, Inc. $94.2M 6.1M 10.0% ▲ 12.9%
Prosight Management, LP $58.4M 3.8M 6.2% ▲ 7.2%
State Street Corp $46.2M 3.0M 4.9% ▲ 22.0%
FMR LLC $37.1M 2.4M 3.9% ▼ 4.8%
Federated Hermes, Inc. $36.1M 2.4M 3.8% ▲ 4241.2%
Point72 Asset Management, L.P. $30.6M 2.0M 3.2% ▲ 72.5%
Vanguard Capital Management LLC $28.5M 1.9M 3.0% ▲ 2.5%
Tcg Crossover Management, LLC $27.5M 1.8M 2.9% 0.0%
Alyeska Investment Group, L.P. $25.3M 1.6M 2.7% ▲ 2.9%
Nantahala Capital Management, LLC $24.9M 1.6M 2.6% ▲ 100.0%
Wellington Management Group LLP $23.2M 1.5M 2.4% ▼ 5.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Janux Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $557,052 11 trades by 7 insiders · 38% under pre-set plans
Net ▼ $557,052 net selling
Insider Date Trade Shares Price Value
Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr June 2, 2026 Sell 4,059 $14.03 $56,948
Dobek Maria Vice President, Accounting May 11, 2026 Sell 2,038 $14.17 $28,878
Dobek Maria Vice President, Accounting January 2, 2026 Sell 1,462 $13.73 $20,073
Mciver Zachariah Chief Medical Officer January 2, 2026 Sell 2,714 $13.73 $37,263
Winter Charles M. Chief Technical Officer January 2, 2026 Sell 2,401 $13.73 $32,966
Campbell David Alan President and CEO January 2, 2026 Sell 8,072 $13.73 $110,829
Diraimondo Thomas Chief Scientific Officer January 2, 2026 Sell 2,505 $13.73 $34,394
Meyer Andrew Hollman Chief Business Officer January 2, 2026 Sell 1,879 $13.73 $25,799
Meyer Andrew Hollman Chief Business Officer December 1, 2025 Sell pre-set plan 2,700 $32.85 $88,695
Meyer Andrew Hollman Chief Business Officer December 1, 2025 Sell pre-set plan 633 $33.52 $21,218
Meyer Andrew Hollman Chief Business Officer November 14, 2025 Sell pre-set plan 3,333 $30.00 $99,990

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Janux Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Janux Therapeutics, Inc. in brief

What does Janux Therapeutics, Inc. do?
Janux Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Janux Therapeutics, Inc.'s stock ticker?
Janux Therapeutics, Inc. trades under the ticker JANX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Janux Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Janux Therapeutics, Inc. reported revenue of $24M, 5367.0% higher than a year earlier, according to its SEC filings.
What is Janux Therapeutics, Inc.'s free cash flow?
Janux Therapeutics, Inc.'s free-cash-flow margin is -174.7% of revenue over the trailing twelve months, ranking 93 of the 176 biotechnology companies we cover.
Who are Janux Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Blackrock, Inc. and Prosight Management, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Janux Therapeutics, Inc.'s market cap?
On November 2, 2026, Janux Therapeutics, Inc.'s market capitalisation was about $1.1B and net debt of -$27.8M. Market figures come from third-party market data and may be delayed.
Who are Janux Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Janux Therapeutics, Inc. are Crispr Therapeutics AG, Abeona Therapeutics Inc., Stoke Therapeutics, Inc., Monte Rosa Therapeutics, Inc. and Tonix Pharmaceuticals Holding Corp. The side-by-side comparison below sets their revenue, margins and growth against Janux Therapeutics, Inc.'s.
Are insiders buying or selling Janux Therapeutics, Inc. stock?
Over the last 12 months, Janux Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Janux Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Janux Therapeutics, Inc. announces its own schedule.